Dopamine Agonists and their Optimality in Treating Parkinson's Disease Compared to Other Treatments


  • Samarth Keerthivasan Pomperaug High School
  • Jotsna Kethar Gifted Gabber
  • Rajagopal Appavu Gifted Gabber



Parkinson's Disease, Cure, Therapy, Treatment


Parkinson’s Disease (PD) is a neurodegenerative disorder that has been plaguing tens of thousands of people each year, and as a result, there has been lots of research to find a drug or compound which, if used correctly, will allow for a decrease in the symptoms of the disorder. One idea that is of question is whether dopamine agonists might be able to help reduce the effects that the disease has upon a person. As a result, the question of how useful dopamine agonists are in the treatment of or minimization of the effects of Parkinson’s Disease rises. This paper focuses heavily on the topic of the optimality of dopamine agonists in the treatment of Parkinson’s disease and relies upon past research on the subject of PD treatments/therapies. Although an agonist, in scientific terms, is known as a chemical substance capable of combining with a specific receptor on a cell and initiating the same reaction or activity typically produced by the original substance itself, these dopamine agonists have not proven to be as effective as can be assumed. These agonists, even with the ability to imitate the reaction of dopamine agonists, are not as useful as other treatments to PD, such as Levodopa. In this paper, comparisons were conducted between the two largest categories of PD therapy to derive a conclusion. The findings indicate some rather surprising results, and prove that dopamine agonists might not be as useful in the treatment of Parkinson’s Disease as one might assume.


Download data is not yet available.

Author Biographies

Jotsna Kethar, Gifted Gabber


Rajagopal Appavu, Gifted Gabber


References or Bibliography

Meder, D., Herz, D. M., Rowe, J. B., Lehéricy, S., & Siebner, H. R. (2018, November 20). The role of dopamine in the brain - lessons learned from Parkinson's disease. NeuroImage. Retrieved January 2, 2022, from

Liu, X., Tang, C., Wen, G., Zhong, C., Yang, J., Zhu, J., & Ma, C. (2019, January 22). The mechanism and pathways of dopamine and dopamine agonists in prolactinomas. Frontiers. Retrieved January 2, 2022, from

Mishra, A., Singh, S., & Shukla, S. (2018, May 31). Physiological and functional basis of dopamine receptors and their role in neurogenesis: Possible implication for parkinson's disease. Journal of experimental neuroscience. Retrieved January 6, 2022, from

Brooks, D. J. (2000, June 1). Dopamine agonists: Their role in the treatment of Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. Retrieved January 2, 2022, from

Auriemma, R. S., Pirchio, R., De Alcubierre, D., Pivonello, R., & Colao, A. (2019, March 11). Dopamine agonists: From the 1970s to Today. Neuroendocrinology. Retrieved January 2, 2022, from

Rizek, P., Kumar, N., & Jog, M. S. (2016, November 1). An update on the diagnosis and treatment of Parkinson’s disease. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. Retrieved January 2, 2022, from

Segura-Aguilar, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., & Zucca, F. A. (2014, March 18). Protective and toxic roles of dopamine in Parkinson's disease. Wiley Online Library. Retrieved January 2, 2022, from

Lawton, M., Ben-Shlomo, Y., May, M. T., Baig, F., Barber, T. R., Klein, J. C., Swallow, D. M. A., Malek, N., Grosset, K. A., Bajaj, N., Barker, R. A., Williams, N., Burn, D. J., Foltynie, T., Morris, H. R., Wood, N. W., Grosset, D. G., & Hu, M. T. M. (2018, July 25). Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression. Journal of neurology, neurosurgery, and psychiatry. Retrieved January 2, 2022, from

Borovac, J. A. (2016, March 24). Side effects of a dopamine agonist therapy for Parkinson’s disease: A mini-review of Clinical Pharmacology. The Yale journal of biology and medicine. Retrieved January 2, 2022, from

Drew, D. S., Muhammed, K., Baig, F., Kelly, M., Saleh, Y., Sarangmat, N., Okai, D., Hu, M., Manohar, S., & Husain, M. (2020, August 6). Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder. Brain: a journal of neurology. Retrieved January 2, 2022, from

Binde, C. D., Tvete, I. F., Gåsemyr, J. I., Natvig, B., & Klemp, M. (2020, July 24). Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: A multiple treatment comparison meta-analysis - European Journal of Clinical Pharmacology. SpringerLink. Retrieved January 2, 2022, from

Picillo, M., Phokaewvarangkul, O., Poon, Y.-Y., McIntyre, C. C., Beylergil, S. B., Munhoz, R. P., Kalia, S. K., Hodaie, M., Lozano, A. M., & Fasano, A. (2021, March). Levodopa versus dopamine agonist after subthalamic stimulation in Parkinson’s disease. US National Library of Medicine. Retrieved January 2, 2022, from

PD MED Collaborative Group. (2014, June 10). Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. The Lancet. Retrieved January 2, 2022, from

Simon. (2018, April 5). Is there NOP hope for parkinson's? The Science of Parkinson's. Retrieved January 6, 2022, from



How to Cite

Keerthivasan, S., Kethar, J., & Appavu, R. (2022). Dopamine Agonists and their Optimality in Treating Parkinson’s Disease Compared to Other Treatments. Journal of Student Research, 11(2).



HS Research Articles